Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective ...

Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study 1 Pre-specified analyses of cognitive endpoints ...

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...

LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient randomized in the United Kingdom Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom Two ...

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...

Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM” or the "Company”) today reported positive progress in a mid-year update from ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701). This is an ASCO Meeting Abstract ...